A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumours
This is a first-in-human, Phase 1, open-label, multicentre, dose-escalation study designed
to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered
intravenously in participants with locally advanced or metastatic solid tumours that have
progressed after all available standard therapy or for which standard therapy has proven to
be ineffective or intolerable, or is considered inappropriate. This study will consist of a
screening period, an initial treatment period, a re-treatment period (for participants who
discontinue MOXR0916 after demonstration of prolonged clinical benefit), and a
post-treatment follow-up period. Participants will be enrolled in two stages: a
dose-escalation stage and an expansion stage. The planned duration of the study is
approximately 3 years.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society